MFN Drug Pricing vs. Congress: The Policy Fight That Could Rewrite Every Rep's Formulary Position
By FieldPulse Staff · March 22, 2026
Tags: policy, drug-pricing, cms, formulary
The Trump administration's push to codify Most Favored Nation drug pricing into law is fracturing Republican support in Congress, even as pharma faces simultaneous pressure from CMS Round 3 negotiations and new pricing agreements. The outcome will determine the commercial model for every specialty drug in America.
The most consequential drug pricing battle in a decade is playing out across Washington in real time — and the outcome will shape how every pharmaceutical rep's portfolio is priced, covered, and contracted for the foreseeable future.
The Trump administration has been aggressively pushing to codify Most Favored Nation (MFN) drug pricing into law.
Under MFN, U.S.
prices for branded pharmaceuticals would be capped at the lowest prices paid by comparable OECD nations — effectively ending the longstanding model in which the U.S.
subsidizes global drug development by paying two to four times what other wealthy nations pay.
Congressional Republicans have so far resisted the measure despite presidential pressure, with a coalition of more than 50 conservative and free-market organizations sending a letter to congressional leaders on March 17, 2026, calling MFN "imported socialist price controls." Pharma companies including Novo Nordisk, J&J, and Pfizer have all cited MFN exposure in their 2026 financial guidance.
The policy pressure is multidimensional.
In the same week, the Pharmaceutical Reform Alliance launched a public petition calling on Congress to pass MFN legislation.
The CMS confirmed all manufacturers of the 15 drugs named for the third round of Medicare price negotiation have agreed to participate, with negotiated prices taking effect in January 2028.
The list includes major commercial workhorses: Jardiance, Farxiga, Xarelto, and Ocrevus.
In December 2025, nine major pharma companies signed pricing agreements with the Trump administration — and simultaneously raised list prices, triggering backlash that has added political fuel to MFN advocates.
What it means for reps: MFN, if passed, would compress net pricing on high-cost specialty drugs — reshaping launch strategies, contracting terms, and formulary negotiations across the industry.
Reps selling in oncology, immunology, and rare disease — categories with the highest list prices and the most MFN exposure — would.
Source: https://www.statnews.com/2026/03/17/mfn-drug-pricing-divide-trump-congress-talks/